Pluri Inc. said China’s National Intellectual Property Administration has granted its subsidiary a patent for a proprietary 3D immune cell expansion and activation system for large-scale manufacturing. The company said the patent complements prior granted protection in the United States and adds to patents in Japan, Korea, Australia and Israel, supporting potential licensing and collaboration for immune cell therapy production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pluri Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656663-en) on February 18, 2026, and is solely responsible for the information contained therein.